Takeaways: Shortening Breyanzi’s required stay-near-centre period and driving ban lowers the logistical and financial barriers to CAR T, which should modestly expand the eligible treat...
Real world evidence (RWE) is rapidly reshaping how therapies are evaluated, approved, and commercialized within global healthcare systems, including Canadian Health. Derived from real world data such ...
Takeaways: Roche’s dual-formulation (IV and SC) authorization for Lunsumio (mosunetuzumab) in Canada creates flexible, fixed-duration access for relapsed/refractory follicular lymphoma...
Takeaways: Health Canada’s decision makes Nucala the first biologic add‑on for eosinophilic COPD in Canada, opening a new high-value segment on top of triple inhaled therapy for patients with fr...
Takeaways: If approved, FILSUVEZ would become Canada’s first treatment specifically for EB-related wounds, addressing a severe unmet need for patients with chronic, painful skin breakdown and he...
Takeaways: This accelerates Italfarmaco’s commercial entry, giving it a platform to negotiate reimbursement and patient access with a distinct HDAC-inhibitor mechanism and a combinatio...
Takeaways: Kashiv BioSciences gets a key regulatory step for its XOLAIR (omalizumab) biosimilar, ADL-018. The market implication is a likely cost-reduction play in a high-value o...
Takeaways: Sunshine Biopharma’s approval for generic rivaroxaban (Xarelto) adds a high-volume, key anticoagulant to its Canadian portfolio and pairs with its existing generic apixaban to create ...
Takeaways: Vimy Pharma’s filing could position it as a domestic, lower-cost semaglutide supplier in Canada, which supports affordability and national supply resilience. The broader market ...
Takeaways: IHEEZO gives Apotex a differentiated, in‑clinic anesthetic that strengthens its positioning with Canadian ophthalmologists and complements its anti‑inflammatory an...
